Products for Research Use Only
RegisterLogin

HL22

CAT: 0013-GTR19250519-01Size: 50 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19250519-01Size:50 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
HL22, a harmine derivative, is a research compound with demonstrated anticancer activity. It inhibits proliferation, migration, and colony formation in cell lines such as HCT116, MGC803, and MCF7, and its multi-pathway metabolic mechanism supports in vitro oncology research.
Smiles
CC1=NCCC2=C1N (C3=C2C=CC (=C3) OC) CCCCCN4C5=C (C=CC (=C5) OC) C6=C4C (=NC=C6) C
Molecular Formula
C31H34N4O2
Molecular Weight
494.627
Storage Conditions
-20°C
Notes
For research use only.

Related Products

CatalogName
GTR19218694-01HL23
GTR19113286-01HL2-m5

Alternative Products

CatalogName
HY-172097HL22
MBS488272-01Anti-CD22 [hL22 (Epratuzumab)]
OAAV00872-200UGCD22 Recombinant Antibody [hL22 (Epratuzumab) ] (OAAV00409)
OAAV00873-200UGCD22 Recombinant Antibody [hL22 (Epratuzumab) ] (OAAV00410)
ENZ-ABS619-0200CD22 Recombinant monoclonal antibody (hL22) (Human IgG1κ)
ENZ-ABS620-0200CD22 Recombinant monoclonal antibody (hL22) (Rabbit IgGκ)
NBP3-13648Rabbit Monoclonal AIF-1/Iba1 Antibody (HL22)
MBS567078-01CD22 Recombinant monoclonal antibody (hL22) (Rabbit IgG kappa)
TA386080CD22 Human Monoclonal Antibody [Clone ID: hL22 (Epratuzumab)]
NBP2-75188-0.025mgHuman Monoclonal Siglec-2/CD22 Antibody (hL22 (Epratuzumab))

Popular Products